Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05700903 · ClinicalTrials.gov registry record · Phase 4
Contributions to Hypertension With Androgen Deprivation Therapy
A Phase 4 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT05700903 is a Phase 4 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 10 participants.
The verdict
NCT05700903, a Phase 4 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a significant role in control of blood pressure. The results from this study will help us understand the ways in which ADT contributes to heart disease and help us develop therapies to prevent heart disease in prostate cancer survivors.
Interventions
- DRUG Placebo
- DRUG Gonadotropin Releasing Hormone Agonists (GNRH)
- DRUG Androgen receptor (AR) inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-09-20 |
| Est. Completion | 2025-07-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05700903
The ClinicalTrials.gov registry entry for NCT05700903 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05700903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05700903 about?
NCT05700903 is a clinical study titled "Contributions to Hypertension With Androgen Deprivation Therapy". This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use...
What is the current status of trial NCT05700903?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2023-09-20. Estimated completion is 2025-07-16.
What interventions are being tested in trial NCT05700903?
The interventions under investigation include: Placebo (DRUG), Gonadotropin Releasing Hormone Agonists (GNRH) (DRUG), Androgen receptor (AR) inhibitor (DRUG).
Who is sponsoring clinical trial NCT05700903?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.